NCT05938361View on ClinicalTrials.gov

Efficacy of Tildrakizumab in Difficult-to-treat Areas in Psoriasis

Active, not recruitingOBSERVATIONAL
Enrollment

120

Participants

Timeline

Start Date

June 1, 2023

Primary Completion Date

November 1, 2024

Study Completion Date

October 15, 2025

Conditions
Psoriasis PalmarisPsoriasis GenitalPsoriasis of ScalpPsoriasis PlantarisPsoriasis Nail
Interventions
OTHER

Psoriasis clinical assessments

Global evaluation of psoriasis and specific evaluation by areas

OTHER

Quality of life evaluation

DLQI questionnaire at each visit

OTHER

Satisfaction assessment

Visual analogic scale at W16, W28, W52

OTHER

Pruritus evaluation

Visual analogic scale at each visit

Trial Locations (1)

75014

Service de Dermatologie- Hopital Saint Joseph, Paris

All Listed Sponsors
lead

Clin4all

NETWORK